香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 $$190d c o p t o i n\pm i\pm j$$ Medcaptain Medical Technology Co., Ltd. 深圳麥科田生物醫療技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 本公告並不構成向任何司法權區的公眾人士提呈出售任何證券的招股章程、發售通函、通知、 通函、小冊子或廣告，亦非出售證券的要約或向公眾人士發出以誘使或招攬收購、購買或認購 證券要約的邀請，且並非旨在邀請公眾人士提出認購或購買任何證券的要約。本公告不應被視 為誘使認購或購買任何證券，亦不擬構成該等勸誘。刊發本公告僅旨在提供有關本公司的資 料，而不作任何其他用途。投資決定不應以本公告所載資料為依據。概不保證將進行發售；任 何證券發售均需刊發最終上市文件，其為投資者作出投資決定所應依賴的唯一文件。概無跡象 顯示本公告所涉及的上市申請已獲批准。 警告 本公告乃根據香港聯合交易所有限公司（「聯交 ...

Core Viewpoint - Reed Jobs, son of Steve Jobs, has launched a venture capital fund focused on innovative medical projects, particularly those aimed at curing cancer, with an initial fund size exceeding $200 million [4][11]. Group 1: Background and Motivation - Steve Jobs passed away from pancreatic cancer in 2011, leaving a legacy that deeply influenced Reed Jobs, who initially aspired to be a doctor to combat cancer [4][7]. - Reed Jobs' journey into venture capital was driven by a desire to participate in the incubation of projects that could advance scientific and medical development [4][11]. Group 2: Career Development - After his father's death, Reed Jobs shifted his academic focus from medicine to history, eventually earning a master's degree from Stanford University [7][12]. - In 2015, he joined the Emerson Collective, a foundation established by his mother, where he began investing in healthcare, initially as a limited partner in established funds [11][12]. Group 3: Investment Strategy and Achievements - Reed Jobs' investment strategy evolved to focus on supporting research teams with innovative ideas that are not yet commercially viable, particularly in cancer treatment [12][13]. - By 2025, the Emerson Collective had invested in over 40 biotech startups, with 8 companies achieving valuations over $200 million through IPOs or acquisitions [13]. Group 4: New Ventures and Future Plans - In 2023, Reed Jobs founded his own venture capital fund, Yosemite, with a mission to ensure cancer is no longer a fatal disease, starting with a fund size of $263 million [13][14]. - The second phase of Yosemite's fundraising has already raised $200 million, with plans to reach a total of $350 million, indicating strong investor interest [14]. Group 5: Broader Impact and Challenges - Reed Jobs has expressed concerns about the state of the U.S. healthcare system, highlighting issues such as outdated technology and declining public trust in institutions [18][19]. - He has considered political involvement to influence healthcare policy but remains focused on his venture capital efforts, aiming to invest in 25 companies through Yosemite [19].

Financial Performance Summary - In 2025, the company achieved operating revenue of 2.33 billion RMB, representing a year-on-year growth of 2.0%, with a notable 13.1% increase in the fourth quarter [2] - The company's overseas revenue reached 840 million RMB, up 17.9% year-on-year, accounting for 36% of total revenue, an increase of 5 percentage points from 2024 [2] - Domestic revenue was 1.47 billion RMB, down 5.5% year-on-year, but showed recovery with a 14.5% increase in the fourth quarter [2] Growth Drivers - The growth was primarily driven by accelerated globalization, with localized operations in 18 countries and over 400 product certifications abroad [2] - The company reported significant growth in new industries, with new industry revenue accounting for 48.5% of total revenue, growing by 8.8% year-on-year [3] - The AI-related revenue constituted 15% of total revenue, an increase of 2.5 percentage points from 2024, indicating a strong integration of AI and automation technologies [5] Profitability and Challenges - The net profit attributable to shareholders was 250 million RMB, a decline of 31.6% year-on-year, influenced by external market conditions and strategic investments [5] - The gross profit margin was 46.8%, affected by the ramp-up of new production capacity, with a slight improvement of approximately 0.7 percentage points in the fourth quarter [5] - The company faced challenges such as trade frictions and the need for ongoing investments in globalization and innovation, which impacted profitability [6]

Core Viewpoint - Beijing Xuanwei Biomedical Technology Co., Ltd. has completed a seed round of financing, focusing on precision medicine in oncology, with investment participation from Meihua Venture Capital [1] Company Overview - Xuanwei Medical is an innovative technology company dedicated to the field of tumor precision medicine, positioning itself with "AI-enabled precision medicine" as its core focus [1] - The company's mission is to "data-driven optimize tumor treatment and clinical practice," specifically addressing the critical pain point of toxic reactions in tumor immunotherapy [1] - Xuanwei Medical aims to become a leading provider of specialized tumor data and intelligent auxiliary diagnosis and treatment services in China [1]

Core Viewpoint - Haineng Technology announced the establishment of Yuanshen Biomedical Technology (Shanghai) Co., Ltd. in collaboration with Mingye Management Consulting (Shanghai) Co., Ltd. to align with its development strategy and operational planning [1] Group 1: Company Structure - The registered capital of Yuanshen Biomedical Technology is set at 2 million yuan, with Haineng Technology contributing 200,000 yuan for a 10% stake [1] - Mingye Management Consulting will invest 1.8 million yuan, holding a 90% ownership in the new company [1]

Group 1: Economic Development and Industry Trends - The year 2026 is anticipated to be a critical juncture for economic development, with various sectors actively engaging in innovation and production to establish a solid foundation for growth [1] - The liquid cooling industry is expected to experience significant growth, driven by the performance, cost, and environmental advantages of silicon-based materials, which are becoming essential for data centers and energy storage [2][3] Group 2: Modular Construction and Global Expansion - CIMC's modular construction project in Cameroon represents a successful integration of research, design, manufacturing, transportation, and construction, showcasing the company's comprehensive capabilities [5] - The project aims to provide a modern office space that meets local needs while enhancing construction efficiency, with completion expected by the second half of 2026 [4] Group 3: Electric Marine Technology - Yidong Technology is advancing the electric boat market with innovative products like the Spirit 2 electric outboard motor, designed for lightweight vessels and featuring a quick-install battery [6][7] - The company has established a global network of over 40 agents and 800 dealers, with plans to expand into emerging markets in South America and Africa by 2026 [8] Group 4: Technological Innovations in Consumer Appliances - Haier has achieved breakthroughs in food preservation technology, utilizing magnetic control to enhance the freshness of perishable items, addressing long-standing industry challenges [10][11] - The company is also innovating in the field of cell therapy with automated systems that improve efficiency and quality, reflecting a commitment to user-driven technological advancements [9][10]

Core Insights - The "12th Shenzhen-Hong Kong (Qianhai) Talent Cooperation Annual Conference" marked the launch of the "Bay Area Talent Pass" platform and the "Shenzhen-Hong Kong HR Alliance," signaling a new phase in talent integration between Shenzhen and Hong Kong [1][3] - The collaboration aims to create a regional innovation community in the Guangdong-Hong Kong-Macao Greater Bay Area, facilitating talent flow and enhancing international recruitment efforts [1][3] Group 1: Talent Integration Initiatives - The "Bay Area Talent Pass" platform focuses on policy recognition and aims to streamline talent evaluation standards between Shenzhen and Hong Kong, providing visa conveniences for foreign talent [3] - The "Shenzhen-Hong Kong HR Alliance" establishes a market-oriented recruitment network to expand the international talent pool [3] - The "Shenzhen 72-Hour Experience Pass" is a key initiative that allows foreign professionals to explore opportunities in the Greater Bay Area, enhancing the region's attractiveness [2][3] Group 2: Innovation and Collaboration - The "Qianhai Jinmaotou" innovation and financing service platform addresses challenges in investment and financing within the tech sector, promoting the integration of talent, capital, industry, and innovation [4][5] - The collaboration between Hong Kong universities and local enterprises aims to facilitate the transfer of research outcomes and attract more talent to Qianhai [6][7] - The "Bay Area Innovation Broker" model is designed to create a closed loop for research, technology transfer, manufacturing, and market expansion, enhancing the flow of innovation resources [7][8] Group 3: Achievements and Future Outlook - Over 1,100 Hong Kong teams have been incubated in Qianhai, with 44 recognized as national high-tech enterprises, showcasing the success of the talent integration efforts [8] - The ongoing initiatives are expected to strengthen the talent magnetism of Qianhai and support the technological innovation landscape in Shenzhen and the Greater Bay Area [8]

Core Viewpoint - Ping An Biomedical Co., Ltd. experienced significant stock price volatility from February 9 to February 13, 2026, with a peak increase of 21.82% followed by a series of declines, indicating low liquidity amplifying price fluctuations [1] Group 1: Stock Performance - On February 9, the stock price surged by 21.82% to $0.27, with a trading volume of $1.0961 million and a turnover rate of 17.59% [1] - The stock faced consecutive declines over the next three trading days, dropping 5.22% to $0.25 on February 10, 5.12% to $0.24 on February 11, and 9.13% to $0.22 on February 12 [1] - A rebound occurred on February 13, with the stock increasing by 3.65% to $0.23, resulting in a total price fluctuation of 30% over the week [1] Group 2: Market Context - During the same period, the textile manufacturing sector saw a slight increase of 0.24%, while the Nasdaq index rose by 0.39%, highlighting the individual performance of the stock compared to its sector and the broader market [1] - The cumulative turnover rate exceeded 50%, further emphasizing the stock's low liquidity and its impact on price volatility [1]

Group 1 - The stock price of Ping An Biomedical Co., Ltd. (stock code: PASW.OQ) fell on February 12, 2026, primarily due to the overall market environment [1] - On the same day, the three major U.S. stock indices all closed lower, with the Nasdaq index down 2.03%, the S&P 500 index down 1.57%, and the Dow Jones index down 1.34% [2] - The decline in technology stocks was attributed to concerns over the disruptive impact of artificial intelligence on industries, coupled with poor U.S. existing home sales data, which heightened risk-averse sentiment [2] Group 2 - As a result of the market conditions, Ping An Biomedical's stock closed down 9.13% at $0.22, with a trading range of 13.42% [2]

Core Viewpoint - The Shanghai International Commercial Court has made significant progress in its first year of operation, handling a total of 2,161 cases with a total amount in dispute exceeding 30 billion yuan by the end of 2025 [3][4]. Group 1: Case Handling and Statistics - The court has resolved 1,743 cases, with a diverse range of parties involved from 56 countries and regions across five continents [3][4]. - The main areas of dispute include international sales contracts, foreign service contracts, foreign contracting disputes, foreign equity transfer disputes, and foreign loan contracts [3][4]. - Specific industries involved in disputes include cross-border investment (131 cases), integrated circuits (120 cases), biomedicine (119 cases), shipping and logistics (73 cases), and enterprises "going global" (65 cases) [3][4]. Group 2: International Judicial Cooperation - The court has prioritized international mutual recognition, handling 30 international judicial assistance cases in 2025, marking a 130% increase year-on-year, with a total amount in dispute of 3.83 billion yuan [4]. - The court has contributed to the construction of international commercial rules, with 13 cases from 2025 included in well-known international databases [4][5]. Group 3: Characteristics of Foreign-related Disputes - Foreign-related business types for enterprises include overseas investments, such as establishing companies or acquiring equity, and undertaking local projects, particularly in "Belt and Road" countries [6]. - Recommendations for enterprises "going global" include resolving disputes through mediation, enhancing compliance systems, and being aware of currency exchange risks [6].